deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02434081

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS)

A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Sponsor: Bristol-Myers Squibb

Conditions Non-small Cell Lung Cancer Stage III
Interventions Nivolumab
Updated 16 times since 2017 Last updated: Aug 23, 2022 Started: Nov 25, 2015 Primary completion: Feb 29, 2020 Completion: Mar 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer Stage III, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 16 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Sep 2017 · 8 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Nov 2021 · 8 months · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2021 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Mar 2021 — Nov 2021 [monthly]

    Completed PHASE2

  2. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Apr 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  10. Sep 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Jan 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • ETOP IBCSG Partners Foundation
  • Frontier Science Foundation, Hellas
Data source: ETOP IBCSG Partners Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations